Baptist Health Hardin, Elizabethtown
Baptist Health Lexington, Lexington
University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Saint Elizabeth Medical Center Edgewood, Edgewood
The University of Louisville, James Graham Brown Cancer Center, Louisville
Owensboro Medical Health System, Owensboro
dan 1 lainnya

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06875310

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Norton Cancer Institute, Louisville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT05983432

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Lexington
Research Site, Louisville
Research Site, Louisville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Lexington

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Lexington Medical Cancer Center Hematology/Oncology, Lexington
University of Louisville, Louisville
Local Institution - 007-388-A, Louisville

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04613596

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Markey Cancer Center, Lexington

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04486833

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Baptist Health Lexington /ID# 261823, Lexington

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06236438

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

Norton Cancer Institute Research, Louisville

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06303505

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

Norton Cancer Institute PARENT, Louisville

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06750185

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

CHI Saint Joseph Cancer Center - East, Lexington
University of Kentucky Chandler Medical Center, Lexington

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

Research Site, Louisville

Menerima pesertaFase 3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07291037

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

St. Elizabeth Healthcare, Edgewood

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019), Lexington

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06731907

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Norton Cancer Institute, Louisville

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT04198766

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center, Lexington
Norton Cancer Institute, Louisville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05142189

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

James Graham Brown Cancer Center (Melanoma/NSCLC), Louisville

Menerima pesertaFase 1/2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT06060613

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

University of Louisville, Louisville

Menerima pesertaFase 2

Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 26 Jun 2026 · NCT04614103

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

Norton Cancer Institute /ID# 248903, Louisville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Jun 2026 · NCT05005403

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

University of Louisville, Louisville

Menerima pesertaFase 1/2

Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05361174

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

UK Markey Cancer Center, Lexington

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05283330

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site, Louisville

Menerima pesertaFase 3

Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 14 Mei 2026 · NCT06417814

A Study of ZW251 in Participants With Advanced Solid Tumors

Norton Cancer Institute, Louisville

Menerima pesertaFase 1

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 7 Mei 2026 · NCT07164313

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Menerima pesertaFase 2

18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

University of Kentucky/Markey Cancer Center, Lexington

Menerima pesertaFase 2/3

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Baptist Health Hardin, Elizabethtown

Menerima pesertaFase 2

Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Apr 2026 · NCT06841055

Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.